Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Biomarkers
Oncologists’ Knowledge and Perspectives on the Use of Biosimilars
Biomarkers
2021 Year in Review - Biosimilars
The findings of a survey of US oncologists indicate that practicing oncologists have gaps in their knowledge about biosimilars.
Read More ›
MicroRNAs Have Promise as Biomarker in Testicular and Other Germ-Cell Tumors
By
Wayne Kuznar
Biomarkers
May 2020, Vol 10, No 5
MicroRNAs have all the characteristics to be a potential game changer as a biomarker in germ-cell tumors (originating in the testes, ovaries, and a few other sites), with high sensitivity, specificity, and clinical validity in pilot studies, said Lucia Nappi, MD, PhD, Medical Oncologist, British Columbia Cancer, Vancouver Centre, Canada, at the 2020 Genitourinary Cancers Symposium.
Read More ›
ASCO Publishes First Guideline on Use of Molecular Biomarkers in Localized Prostate Cancer
By
Rebecca Bailey
Biomarkers
May 2020, Vol 10, No 5
The clinical course of prostate cancer is highly variable, reflecting the heterogeneity of the disease. Although most men diagnosed with prostate cancer have low-risk, favorable disease characteristics, some may harbor aggressive features and experience disease progression despite conventional therapy. Therefore, initial risk stratification is vitally important for determining effective treatment strategies and improving clinical outcomes.
Read More ›
MSI-H a Marker for Lynch Syndrome, a More Common Condition Than Generally Expected
By
Wayne Kuznar
Biomarkers
September 2018, Vol 8, No 9
Tumors with high microsatellite instability (MSI-H) are predictive of Lynch syndrome. The recent approval of the first immunotherapies for use in patients with MSI-H or with mismatch repair-deficiency (dMMR) in solid tumors is now leading to routine testing for MSI-H or dMMR in patients with advanced solid tumors.
Read More ›
Best Practices: Evolving Understanding of Molecular Diagnostics and Biomarkers in Lung Cancer
By
Geoff Oxnard, MD
;
Lauren Ritterhouse, MD, PhD
2018 ASCO Highlights
,
Biomarkers
,
Interview with the Innovators
September 2018, Vol 8, No 9
At ASCO 2018,
Oncology Practice Management
(
OPM
) discussed the current state of genetics and genomic testing, the increasing understanding of biomarkers, and how they influence the treatment of patients with lung cancer.
Read More ›
Best Practices: Use of Biomarkers in the Treatment of Patients with Lung Cancer
By
Roy S. Herbst, MD, PhD
;
David L. Rimm, MD, PhD
2018 ASCO Highlights
,
Biomarkers
,
Interview with the Innovators
August 2018, Vol 8, No 8
At ASCO 2018,
Oncology Practice Management
(
OPM
) spoke with Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Director for Translational Research at Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT, and David L. Rimm, MD, PhD, Professor of Pathology, Yale University School of Medicine, about the increasing role of biomarkers in the management of patients with lung cancer.
Read More ›
View the Latest Issue of OPM
Read Issue
Top Trending Articles
1.
Molecular Characteristics Increasingly Define Adult Gliomas
By
William King
2.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
By
William King
3.
Optimal Systemic Therapy for Renal Cell Carcinoma Is Still Evolving
By
William King
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
2022 Midyear Review: Non–Small-Cell Lung Cancer
2022 Oncology Biosimilar Guide to Patient Support Services
2022 Breast Cancer Guide to Patient Support Services
Browse By Topic
Practice Management
Financial Management
Reimbursement
Health Policy
Quality Care
ICD Codes
Survivorship
FDA Approvals, News & Updates
In the News
Guide to Patient Support Services
Index
Introduction
2023 Spotlight: Amgen
Conference Correspondent
ASCO 2022 - Wrap Up
NSCLC IO 2022 - Midyear Review
SABCS 2021 Wrap-Up
Dual IO 2021 Year in Review
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Webinars
Rapid Reactions
In the News
Quick Quiz
Multiple Myeloma Monthly Minutes
Melanoma Monthly Minutes
Press Releases
Women's Health Monthly Minutes
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes